Home » Newsletters » BioWorld

BioWorld

Jan. 19, 1993

View Archived Issues

GENSIA APPLIES TO MARKET ARASINE IN EUROPE

MYCOGEN DEAL WITH FORAGE GENETICS

GI LICENSES FACTOR IX PROTEIN

CYTOGEN SHIPS ONCOSCINT

CANGUARD PACT WITH ATHENA

CHIRON ESTABLISHES MARKETER

AIS LICENSES ANTI-CD34 ANTIBODIES

APPLIED BIOSCIENCE CONSOLIDATES COMPANIES

PHOTODYNAMIC SKIN TUMOR TREATMENT 'EFFECTIVE'

GLAXO EXPANDS STAKE IN BIOCHEM PHARMA

VESTAR DONATES DRUG TO KS PATIENTS

SUGEN JOINS FORCES WITH SELECTIDE

CENTOCOR HALTS TRIALS; STOCK PLUMMETS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
Medline plans record-setting $5.37B IPO
BioWorld MedTech
Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Flow Neuro wins FDA nod for at-home device for depression
BioWorld MedTech
Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...